Exavir Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Exavir Therapeutics?

Exavir Therapeutics has 3 investors including National Institute of Allergy and Infectious Diseases And Gilead Sciences.

Q: How much funding has Exavir Therapeutics raised to date?

Exavir Therapeutics has raised obfuscated.

Overview

Exavir Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Exavir Therapeutics

CB Rank

88505

Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.

Founded

obfuscation

Private

Grant

San Francisco, California, United States

11-50

exavirtherapeutics.com/

Biotechnology

Health Care

Medical

Therapeutics

Funding Rounds

Grant

OBF

obfuscation

Seed

OBF

obfuscation

Details

Legal Name

Exavir Therapeutics, Inc.

Operating Status

Active

Company Type

For Profit

About the Company

Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiviral therapeutics.

Contact Email

media@exavirtx.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

VH-310 (previously XV-110)

An ultra-long-acting prodrug of cabotegravir designed for dosing intervals of six months or longer, currently in Phase 1 clinical study.

XV-122

A long-acting prodrug of dolutegravir designed for dosing intervals up to four months and compatible with self-administration via auto-injector.

Research & Development

Exavir Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant
obfuscated obfuscation	Grant - Exavir Therapeutics	1	obfuscated obfuscation	National Institute of Allergy and Infectious Diseases	Grant

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
National Institute of Allergy and Infectious Diseases	Yes	Grant - Exavir Therapeutics	—
National Institute of Allergy and Infectious Diseases	Yes	Grant - Exavir Therapeutics	—
National Institute of Allergy and Infectious Diseases	Yes	Grant - Exavir Therapeutics	—
National Institute of Allergy and Infectious Diseases	Yes	Grant - Exavir Therapeutics	—
National Institute of Allergy and Infectious Diseases	Yes	Grant - Exavir Therapeutics	—